drugset
drugset / Trial / NCT07437105

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants

NCT07437105 ↗

Phase 1 Recruiting 128 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272.

Timeline

Start
2026-02-25
Primary completion
2027-03-23
Completion
2027-03-23

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-272 Unknown — Oral

Indications

cystic fibrosis